Fenbendazole + Curcumin Interaction

⚠️ RESEARCH-BASED INTERACTION DATA — NOT COMPREHENSIVE.

Interaction Type: additive | Evidence Level: preliminary

Fenbendazole and curcumin target different anti-cancer mechanisms — microtubule disruption and NF-κB/inflammation respectively. The combination is referenced in the Joe Tippens protocol.

Mechanism of Interaction

Fenbendazole disrupts microtubule polymerization and inhibits GLUT4-mediated glucose uptake in cancer cells. Curcumin inhibits NF-κB (reducing survival signaling), induces apoptosis via mitochondrial pathway, and has anti-angiogenic effects. The combination attacks cancer through metabolic (Warburg effect targeting), structural (cytoskeletal disruption), and signaling (NF-κB suppression) mechanisms simultaneously.

Clinical Relevance

Based on case reports only (Tippens protocol). No controlled clinical trials of this specific combination. Both compounds individually have preclinical anti-cancer evidence. The combination is widely discussed in patient communities.

Recommendations

• Both are CYP3A4 substrates — potential metabolic competition
• Take with fatty meal to enhance absorption of both compounds
• Monitor liver function tests (both have hepatic metabolism)
• This combination is not evidence-based for cancer treatment — discuss with oncologist

Relevant Conditions

• Cancer (adjunctive, not replacement for standard treatment)
• Drug repurposing research